Sign In
Buy ABSI
$5.94
-0.410 (-6.46%)
At Close: Jun 03, 2026
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
02:05am, Monday, 13'th Jan 2025
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair lo
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30am, Friday, 10'th Jan 2025
Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class thera
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
07:00am, Wednesday, 08'th Jan 2025
$20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software $20 Million Equity Inve
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
08:00am, Monday, 06'th Jan 2025
Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci's
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
10:01am, Tuesday, 12'th Nov 2024
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO an
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
09:51am, Tuesday, 12'th Nov 2024
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
07:30am, Tuesday, 12'th Nov 2024
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
Absci to Host R&D Day on December 12, 2024
08:00am, Thursday, 07'th Nov 2024
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
08:00am, Tuesday, 15'th Oct 2024
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business up
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
12:36pm, Thursday, 03'rd Oct 2024
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to di
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:30am, Friday, 30'th Aug 2024
Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August.
Absci to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 21'st Aug 2024
VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating i
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
11:50pm, Friday, 16'th Aug 2024
Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
06:31pm, Wednesday, 14'th Aug 2024
Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
04:01pm, Wednesday, 14'th Aug 2024
Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development
